The market expected roughly $828M of revenue and about $0.10-$0.12 of adjusted EPS. The published consensus called for approximately $828.43M in revenue, adjusted EPS near $0.10-$0.12, and EBIT of roughly $36.6M.
| Metric | Q1 FY27 | Q1 FY26 | Market read |
|---|---|---|---|
| Net sales | $843M (Financial Highlights) | $723M | Above ~$828M consensus |
| Organic revenue growth | 15.8% (Organic Revenue table) | — | Above prior FY27 framework of approximately 10% |
| Operating income | $5M (Income Statement) | $(13)M | Well below ~$36.6M consensus EBIT |
| Net income attributable to Company | $0M (Income Statement) | $(19)M | — |
| Diluted EPS | $0.00 (Income Statement) | $(0.08) | Below adjusted consensus of ~$0.10-$0.12 |
| Weighted average shares | 281.0M (Income Statement) | 252.8M | Higher dilution |
| CGM sales | $431M (Segment results) | $360M | Up 19.9% |
Revenue was the clear beat, but the quality of that beat was mixed. Worldwide sales reached $843M, up 16.6% reported and 15.8% organically, exceeding consensus by roughly $15M. The underlying growth still cleared the company’s roughly 10% FY27 organic-growth framework, but the quarter included a larger extra-week benefit than the annual outlook had assumed, reducing the upside’s persistence.
Profitability was the decisive miss. Operating income improved from a $13M loss to only $5M of profit, while the market had been looking for EBIT around $36.6M. The filing gives no adjusted-profit bridge explaining the gap, so the bottom-line comparison is not perfectly apples-to-apples; nevertheless, reported GAAP EPS was $0.00 and net income attributable to the company was effectively zero. Expenses also remained heavy: selling, general and administrative costs rose to $312M from $283M, and weighted-average shares increased to 281.0M from 252.8M.
The growth engine is working, but this quarter does not yet prove operating leverage. CGM revenue rose 19.9% to $431M, pumps grew 21.5% to $144M, and international sales increased 18.1% to $603M (Segment results). The company also said its pipeline advanced ahead of schedule, including FDA submission for MiniMed Fit and completion of Vivera pivotal-trial enrollment. 〔0〕 Those developments support the longer-term product story, but they do not offset the near-term earnings miss. Net read: a revenue beat overshadowed by unexpectedly weak profitability.
Read the original 8-K on SEC EDGAR ↗